



## **Raphael Pharmaceutical Inc. Announces Positive Clinical Proof-of-Concept Results for Cannabinoid-Based Formula in Rheumatoid Arthritis**

Raphael Pharmaceutical Inc. is delighted to announce the successful completion of a clinical proof-of-concept study evaluating the company's cannabinoid-based formula for the management of rheumatoid arthritis (RA). Conducted in the United States under IRB approval and in compliance with FDA regulations, the study was managed by the highly regarded CRO Citruslabs.

The single-group clinical trial involved 12 adult participants, each of whom used 0.5 mL of Raphael's formula daily over an 8-week period. The study results demonstrate promising efficacy, with significant improvements observed in critical health outcomes, including pain levels, sleep quality, and overall well-being. These benefits became evident as early as Week 4 and were sustained through the end of the trial.

### **Key Findings**

**Reduction in Disease Activity Score (DAS28):** The Disease Activity Score (DAS28)—a comprehensive metric assessing RA disease activity—declined by 19.2%, reflecting a shift in participants from high to moderate disease activity. DAS28 is a widely used measure of RA disease activity that combines the number of tender and swollen joints, levels of inflammation, and the patient's self-assessed health. A lower DAS28 score indicates reduced disease activity, and achieving low scores is a key goal in RA management.

- Participants in remission increased from 0% at baseline to 16.67% by Week 8.
- Low disease activity prevalence rose from 8.33% to 16.67%.
- High disease activity prevalence decreased from 66.67% at baseline to 41.67%.

### **Improved Symptom Reporting:**

- Pain-related symptoms improved significantly, with participants reporting a reduction in negative pain outcomes from 75% at baseline to 50% by Week 8.
- Morning stiffness also showed notable improvement, decreasing from 75% at baseline to 41.67% at Week 8.

### **Patient Satisfaction and Feedback:**

**83.33%** of participants expressed a desire to continue using the product.

**91.67%** indicated they would recommend the formula to others living with RA.

### **Biomarker Analysis**

Although blood biomarker analysis did not reveal statistically significant changes, the overall findings emphasize the clinical potential of Raphael's formula.

**These encouraging findings highlight the potential of Raphael's cannabinoid-based formula to enhance the quality of life for individuals living with RA.**

